Squarepoint
RPRX icon

Squarepoint’s Royalty Pharma RPRX Stock Holding History

Squarepoint’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.3M Sell
326,641
-1,022,875
-76% -$53.2M 0.02% 738
2026
Q1 		$64.7M Sell
1,349,516
-206,725
-13% -$9.05M 0.08% 259
2025
Q4 		$60.1M Buy
1,556,241
+870,454
+127% +$33.2M 0.06% 345
2025
Q3 		$24.2M Buy
685,787
+412,457
+151% +$14.9M 0.02% 648
2025
Q2 		$9.85M Buy
+273,330
New +$9.06M 0.01% 1080
2025
Q1 		– Sell
-384,132
Closed -$9.8M – 5286
2024
Q4 		$9.8M Sell
384,132
-234,551
-38% -$6.22M 0.01% 1171
2024
Q3 		$17.5M Buy
618,683
+217,157
+54% +$6.02M 0.03% 656
2024
Q2 		$10.6M Sell
401,526
-222,513
-36% -$6.17M 0.02% 909
2024
Q1 		$19M Sell
624,039
-276,855
-31% -$8.16M 0.03% 641
2023
Q4 		$25.3M Sell
900,894
-55,662
-6% -$1.53M 0.05% 459
2023
Q3 		$26M Buy
956,556
+521,226
+120% +$15.5M 0.06% 347
2023
Q2 		$13.4M Sell
435,330
-79,379
-15% -$2.69M 0.04% 537
2023
Q1 		$18.5M Buy
514,709
+227,440
+79% +$8.43M 0.08% 300
2022
Q4 		$11.4M Buy
287,269
+195,214
+212% +$8.15M 0.04% 445
2022
Q3 		$3.7M Sell
92,055
-85,185
-48% -$3.64M 0.02% 936
2022
Q2 		$7.45M Sell
177,240
-3,413
-2% -$140K 0.04% 511
2022
Q1 		$7.04M Sell
180,653
-188,375
-51% -$7.4M 0.03% 571
2021
Q4 		$14.7M Buy
369,028
+132,435
+56% +$5.14M 0.04% 400
2021
Q3 		$8.55M Buy
236,593
+60,441
+34% +$2.35M 0.02% 561
2021
Q2 		$7.22M Buy
176,152
+161,570
+1,108% +$6.87M 0.03% 583
2021
Q1 		$636K Sell
14,582
-6,611
-31% -$313K ﹤0.01% 1846
2020
Q4 		$1.06M Buy
+21,193
New +$899K 0.01% 1293
2020
Q3 		– Sell
-200,000
Closed -$9.71M – 2791
2020
Q2 		$9.71M Buy
+200,000
New +$9.9M 0.16% 172

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Squarepoint's RPRX Position: Q2 2026 in Review

Squarepoint reduced its Royalty Pharma (RPRX) stake by 76% in Q2 2026, selling an estimated $53.2M and leaving 326,641 shares worth $18.3M. The position accounts for 0.02% of the portfolio, ranked #738.

Squarepoint first reported a position in RPRX in Q2 2020 and has held it in 23 quarters since. The position peaked at $64.7M in Q1 2026. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Squarepoint held 326,641 shares of Royalty Pharma worth $18.3M as of Q2 2026.
  • Squarepoint sold 1,022,875 Royalty Pharma shares in Q2 2026, an estimated $53.2M.
  • Royalty Pharma made up 0.02% of Squarepoint's portfolio in Q2 2026, its #738 holding.
  • Squarepoint first reported a position in Royalty Pharma in Q2 2020 and has held it in 23 quarters since.
  • Squarepoint's Royalty Pharma position peaked at $64.7M in Q1 2026.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.